Clinical bottom line
Psychedelic-assisted therapies, particularly psilocybin, show promising rapid antidepressant effects in treatment-resistant depression (TRD), with some patients achieving remission after limited dosing sessions. However, evidence on the durability of these effects remains preliminary, and safety profiles require further characterization. Current data support cautious optimism but underscore the need for rigorous, controlled trials to define optimal protocols, patient selection, and long-term outcomes before widespread clinical adoption (Sabani et al., 2026; Ledwos et al., 2022).
What the evidence shows
Treatment-resistant depression, defined by failure to respond to multiple antidepressant trials, remains a major clinical challenge (Bartova et al., 2025). Psilocybin-assisted therapy has emerged as a candidate intervention, leveraging serotonergic psychedelic mechanisms to potentially reset dysfunctional neural circuits implicated in depression.
Sabani et al. (2026) reviewed psilocybin trials in TRD, reporting rapid remission in a subset of patients following one or two dosing sessions combined with psychotherapy. The antidepressant effects often manifested within hours to days, contrasting with the delayed onset typical of conventional antidepressants. However, the durability of response varied, with some patients relapsing within weeks to months, highlighting the need for maintenance strategies.
Haniff et al. (2024) discussed the neurobiological rationale, noting psilocybin’s modulation of neuroplasticity, inflammation, and serotonergic signaling pathways relevant to both depression and neurodegenerative processes. This suggests potential dual benefits in mood and cognitive domains, warranting exploration in comorbid populations.
Chmiel et al. (2026) identified predictors of psychedelic efficacy, including baseline symptom severity, psychological openness, and therapeutic context, emphasizing the importance of patient selection and set/setting in optimizing outcomes.
Ledwos et al. (2022) critically appraised the evidence, cautioning that many studies are small, open-label, or lack active comparators, limiting generalizability. They highlighted gaps in safety data, especially regarding adverse psychological events and long-term effects.
Feilding-Mellen et al. (2023) discussed practical considerations for integrating psychedelics into TRD treatment, including regulatory hurdles, training requirements, and the need for standardized protocols.
Caveats and uncertainty
The current evidence base is limited by small sample sizes, heterogeneity in dosing regimens, and variable psychotherapy adjuncts. Most trials have short follow-up periods, leaving the long-term efficacy and safety profile unclear. The risk of adverse events, including transient anxiety, psychosis-like symptoms, and potential for misuse, requires systematic monitoring (Ledwos et al., 2022).
Furthermore, the mechanisms underlying response variability are incompletely understood, complicating patient stratification. The impact of comorbidities, concurrent medications, and demographic factors on outcomes remains underexplored (Chmiel et al., 2026).
Regulatory frameworks and clinical guidelines for psychedelic therapies are evolving, and current use outside research settings is limited. Ethical considerations around informed consent and therapeutic setting are paramount.
How this may change practice
Clinicians should remain informed about emerging psychedelic research as a potential option for TRD, particularly for patients unresponsive to standard treatments. While routine clinical use is premature, referral to clinical trials or specialized centers may be appropriate for selected patients.
Psychedelic-assisted therapy may complement existing pharmacological and psychotherapeutic approaches, potentially reducing treatment latency and improving remission rates. However, integration into practice will require multidisciplinary collaboration, clinician training, and infrastructure development to ensure safety and efficacy.
Ongoing research may clarify optimal dosing, maintenance strategies, and patient selection criteria, ultimately informing evidence-based guidelines. Until then, clinicians should approach psychedelics as experimental interventions with promising but not yet definitive evidence.